About bionano genomics inc - BNGO
Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The firm engages in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. Its products include Saphyr, Bionano Chips, Bionano Prep Kits, and Bionano Data Solutions. The company was founded by Han Cao in January 2003 and is headquartered in San Diego, CA.
BNGO At a Glance
Bionano Genomics, Inc.
9540 Towne Centre Drive
San Diego, California 92121
| Phone | 1-858-888-7600 | Revenue | 28.51M | |
| Industry | Biotechnology | Net Income | -26,395,000.00 | |
| Sector | Health Technology | Employees | 97 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
BNGO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.292 |
| Price to Book Ratio | 0.37 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.183 |
| Enterprise Value to Sales | -0.151 |
| Total Debt to Enterprise Value | -3.92 |
BNGO Efficiency
| Revenue/Employee | 293,896.907 |
| Income Per Employee | -272,113.402 |
| Receivables Turnover | 5.47 |
| Total Asset Turnover | 0.379 |
BNGO Liquidity
| Current Ratio | 1.978 |
| Quick Ratio | 1.642 |
| Cash Ratio | 1.287 |
BNGO Profitability
| Gross Margin | 21.952 |
| Operating Margin | -116.946 |
| Pretax Margin | -92.353 |
| Net Margin | -92.588 |
| Return on Assets | -35.134 |
| Return on Equity | -66.154 |
| Return on Total Capital | -43.046 |
| Return on Invested Capital | -59.015 |
BNGO Capital Structure
| Total Debt to Total Equity | 38.029 |
| Total Debt to Total Capital | 27.551 |
| Total Debt to Total Assets | 22.959 |
| Long-Term Debt to Equity | 13.436 |
| Long-Term Debt to Total Capital | 9.734 |